Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2016 Aug:10:164-73.
doi: 10.1016/j.ebiom.2016.07.004. Epub 2016 Jul 6.

Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review

Lesley Uttley  1 , Becky L Whiteman  2 , Helen Buckley Woods  1 , Susan Harnan  1 , Sian Taylor Philips  3 , Ian A Cree  4 ; Early Cancer Detection Consortium
Affiliations
Meta-Analysis

Building the Evidence Base of Blood-Based Biomarkers for Early Detection of Cancer: A Rapid Systematic Mapping Review

Lesley Uttley et al. EBioMedicine. 2016 Aug.

Abstract

Background: The Early Cancer Detection Consortium is developing a blood-test to screen the general population for early identification of cancer, and has therefore conducted a systematic mapping review to identify blood-based biomarkers that could be used for early identification of cancer.

Methods: A mapping review with a systematic approach was performed to identify biomarkers and establish their state of development. Comprehensive searches of electronic databases Medline, Embase, CINAHL, the Cochrane library and Biosis were conducted in May 2014 to obtain relevant literature on blood-based biomarkers for cancer detection in humans. Screening of retrieved titles and abstracts was performed using an iterative sifting process known as "data mining". All blood based biomarkers, their relevant properties and characteristics, and their corresponding references were entered into an inclusive database for further scrutiny by the Consortium, and subsequent selection of biomarkers for rapid review. This systematic review is registered with PROSPERO (no. CRD42014010827).

Findings: The searches retrieved 19,724 records after duplicate removal. The data mining approach retrieved 3990 records (i.e. 20% of the original 19,724), which were considered for inclusion. A list of 814 potential blood-based biomarkers was generated from included studies. Clinical experts scrutinised the list to identify miss-classified and duplicate markers, also volunteering the names of biomarkers that may have been missed: no new markers were identified as a result. This resulted in a final list of 788 biomarkers.

Interpretation: This study is the first to systematically and comprehensively map blood biomarkers for early detection of cancer. Use of this rapid systematic mapping approach found a broad range of relevant biomarkers allowing an evidence-based approach to identification of promising biomarkers for development of a blood-based cancer screening test in the general population.

Keywords: Assay; Biomarker; Blood; Cancer; Diagnosis; Early detection; Systematic review.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Modified PRISMA 2009 flow diagram.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Barak V., Holdenrieder S., Nisman B., Stieber P. Relevance of circulating biomarkers for the therapy monitoring and follow-up investigations in patients with non-small cell lung cancer. Cancer Biomark. 2010;6(3–4):191–196. - PubMed
    1. Beije N., Jager A., Sleijfer S. Circulating tumor cell enumeration by the CellSearch system: the clinician's guide to breast cancer treatment? Cancer Treat. Rev. 2015;41(2):144–150. - PubMed
    1. Berruti A., Torta M., Piovesan A. Biochemical picture of bone metabolism in breast cancer patients with bone metastases. Anticancer Res. 1995;15(6B):2871–2875. - PubMed
    1. Clancy C., Joyce M.R., Kerin M.J. The use of circulating microRNAs as diagnostic biomarkers in colorectal cancer. Cancer Biomark. 2014 - PubMed
    1. Cochrane A.L., Holland W.W. Validation of screening procedures. Br. Med. Bull. 1971;27(1):3–8. - PubMed

Substances